Low molecular weight peptidomimetic growth hormone secretagogues

The compound represented by structural Formula (IV)

• where
• Ar1 and Ar2 are each independently selected from indoyl,
• Ar3 is selected from the group
• n and o are independently 1, 2 or 3;
• RA is selected from the group
• C0-C3alkyl-heterocycle where the heterocycle comprises a mono-, bi-, or tricycle containing 5-12 ring atoms, one or two of which are heteroatoms selected from O, S, and N, provided at least one heteroatom is N, where any N atom is optionally substituted with R1,
• C0-C6alkyl substituted with one or two substituents selected from
• the group
• NR2R3,
• imidazolinyl,
• pyridinyl,
• dihydropyridinyl, and
• piperidinyl;
• RB, RC, RD, and RE are selected from the group
• hydrogen,
• C1-C6alkyl optionally substituted with a group selected from
• NR2R3, and
• phenyl-C1-C3—NR2R3, and
• halo(F, Cl, Br, I)C1-C6alkyl;
• R1 is selected from
• hydrogen,
• C1-C6alkyl,
• C(═O)—C1-C6alkyl,
• C(═O)—NR2R3,
• C(═NR2)—NR2R3,
• C(═O)O—C1-C6alkyl, and
• halo(F, Cl, Br, I)C1-C6alkyl;
• R2 and R3 are independently selected from
• hydrogen,
• C1-C6alkyl,
• piperidinyl, and
• halo(F, Cl, Br, I)C1-C6alkyl;
• R2 and R3 together with the N to which they are bonded may form a 5- or 6-member heterocycle, optionally containing one additional hetero atom selected from O, S, and N where any N is optionally substituted with R1, any carbon is optionally substituted with R6 and where the heterocycle is optionally fused to a phenyl ring, optionally substituted with R4;
• R4 and R5 are independently selected from the group
• hydrogen,
• halo(F, Cl, Br, and I),
• cyano,
• amino,
• amido,
• nitro,
• hydroxy,
• C1-C6alkyl optionally substituted with 1-3 R6,
• C2-C6alkynyl optionally substituted with 1-3 R6,
• C1-C6alkyloxy optionally substituted with 1-3 R6,
• C1-C6acylamino optionally substituted with 1-3 R6,
• C1-C6alkylcarbonyl optionally substituted with 1-3 R6,
• C1-C6alkyloxycarbonyl optionally substituted with 1-3 R6,
• N—(C1-C6alkyl), N—(C1-C6acyl)amino optionally substituted with 1-3 R6,
• N—(C1-C6alkyl)carboxamido optionally substituted with 1-3 R6,
• N,N-di(C0-C6alkyl)amino optionally substituted with 1-3 R6,
• N,N-di(C1-C6alkyl)carboxamido optionally substituted with 1-3 R6,
• C1-C4perfluoroalkyl, and
• C1-C3perfluoroalkoxy;
• R6 is selected from the group
• COOR2,
• CONR2R3,
• O(C═O)R2,
• cyano,
• NR2R3,
• NR2COR3,
• azido,
• nitro, and
• hydroxy;
• R7 is selected from the group
• R6, and
• C6-C10aryl optionally substituted with
• halo(F, Cl, Br, and I),
• cyano,
• amino,
• amido,
• nitro,
• hydroxy,
• C1-C4perfluoroalkyl, and
• C1-C3perfluoroalkoxy;
• Z is selected from the group
• C1-C6alkyl substituted with 1-2 R7,
• C2-C6alkynyl optionally substituted with 1-2R7,
• C2-C6alkyenyl optionally substituted with 1-2 R7, and
• C1-C6alkyloxy optionally substituted with 1-2 R7,
• Z and RE together with the N to which they are bonded may form a 5- or 6-member heterocycle, optionally containing one additional hetero atom selected from O, S, and N where any N is optionally substituted with R1, any carbon is optionally substituted with R7 and where the heterocycle is optionally fused to a phenyl ring;
• and
• pharmaceutically acceptable salts thereof.